Previous 10 | Next 10 |
SEATTLE, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal third quarter 2023 financial results on Monday, January 9, 2023, after the market closes. In conjunction, the company w...
Accolade Champions Health Equity and Welcomes FOLX Health to Trusted Partner Ecosystem at HLTH 2022 PR Newswire Chief Medical Officer Dr. Shantanu Nundy and Dr. Jay Bhatt , Managing Director at Deloitte, explore the role of employers in removing barriers to equ...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
Summary Accolade outperformed in Q2 2023 on another strong quarter of double-digit revenue growth. Full-year guidance has moved slightly higher, but there remains ample room for more upward revisions. With the fundamentals firmly intact despite the ongoing macro challenges, th...
Accolade Inc. (ACCD) Q2 2023 Earnings Conference Call October 06, 2022, 04:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of I...
Accolade press release ( NASDAQ: ACCD ): Q2 GAAP EPS of -$0.66 beats by $0.06 . Revenue of $87.6M (+19.5% Y/Y) beats by $4.74M . For the fiscal third quarter ending November 30, 2022, we expect: Revenue between $86 million and $88 million vs $89.3M Co...
Fiscal second quarter 2023 revenue of $87.6 million, a 20% increase compared to fiscal second quarter 2022 revenue of $73.3 million SEATTLE, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August...
Accolade ( NASDAQ: ACCD ) is scheduled to announce Q2 earnings results on Thursday, October 6th, after market close. The consensus EPS Estimate is -$0.50 (+48.5% Y/Y) and the consensus Revenue Estimate is $82.86M (+13.1% Y/Y). Over the last 1 year, ACCD has beaten EP...
SEATTLE, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal second quarter 2023 financial results on Thursday, October 6, 2022, after the market clos...
Truist named IT-driven health services companies Accolade ( NASDAQ: ACCD ) and Privia Health Group, Inc. ( PRVA ) as its favorites in launching coverage in the Healthcare IT/Digital Health space, citing a long-term positive trend. “….we believe the digita...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...